A 52-year-old man from Delhi presents with a 2-month history of progressive weakness, bleeding gums, and petechial rash. On examination, he is cachectic with hepatomegaly (3 cm below costal margin) and no lymphadenopathy. Laboratory investigations show: Hb 6.8 g/dL, WBC 1200/μL (with 8% blasts), platelets 20,000/μL. Bone marrow aspiration reveals 22% blasts with Auer rods. Cytochemistry: MPO positive, PAS negative. Flow cytometry confirms AML with t(15;17). What is the next most appropriate step in management?

Explanation

## Diagnosis: Acute Promyelocytic Leukemia (APL) with t(15;17) ### Recognition of APL **Key Point:** Acute promyelocytic leukemia (AML-M3) is a distinct subtype of AML characterized by t(15;17) translocation, which fuses the PML gene on chromosome 15 with the RARA (retinoic acid receptor alpha) gene on chromosome 17. ### Diagnostic Features in This Case | Feature | Finding | Significance | |---------|---------|---------------| | **Morphology** | Auer rods present | Characteristic of APL (often multiple/bundle-like) | | **Cytochemistry** | MPO positive, PAS negative | Myeloid differentiation | | **Cytogenetics** | t(15;17) | Pathognomonic for APL | | **Blast percentage** | 22% | Diagnostic for AML (>20%) | | **Clinical** | Bleeding, petechiae | DIC-prone subtype | **High-Yield:** APL is the ONLY AML subtype where the standard 7+3 regimen is NOT the first-line therapy. ATRA + ATO is now the standard of care and has revolutionized APL outcomes. ### Why ATRA + ATO, Not 7+3? 1. **Mechanism of ATRA:** Binds to PML-RARA fusion protein, causing differentiation of leukemic promyelocytes into mature neutrophils and apoptosis 2. **Mechanism of ATO:** Causes degradation of PML-RARA protein, inducing differentiation and apoptosis 3. **Synergy:** Combined ATRA + ATO achieves complete remission in >90% of APL cases with minimal toxicity 4. **Superior outcomes:** ATRA + ATO is superior to conventional chemotherapy in both newly diagnosed and relapsed APL **Clinical Pearl:** APL is the most curable AML subtype (5-year OS >80% with ATRA + ATO), but only if recognized early and treated with targeted therapy rather than conventional chemotherapy. ### Critical Management Points **Warning:** APL patients are at extreme risk for disseminated intravascular coagulation (DIC) due to release of procoagulant substances from abnormal promyelocytes. This patient's bleeding gums and petechiae suggest early DIC. **Urgent steps:** - Start ATRA + ATO immediately (do NOT wait for additional confirmatory tests) - Aggressive supportive care: FFP, platelets, cryoprecipitate to manage DIC - Monitor PT/INR, fibrinogen, D-dimer closely - Avoid conventional chemotherapy (7+3), which worsens DIC **Mnemonic:** **APL-ATRA** — **A**cute **P**romyelocytic **L**eukemia responds to **A**ll-**T**rans **R**etinoic **A**cid (+ arsenic trioxide).